Article
Immunology
Eugene Athan, James Baber, Karen Quan, Robert J. Scott, Anna Jaques, Qin Jiang, Wen Li, David Cooper, Mark W. Cutler, Elena Kalinina, Annaliesa S. Anderson, Kena A. Swanson, William C. Gruber, Alejandra Gurtman, Beate Schmoele-Thoma
Summary: This study demonstrates the noninferiority of immune responses with coadministration of RSVpreF and SIIV in an older-adult population, and shows that the coadministration has an acceptable safety and tolerability profile.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Biotechnology & Applied Microbiology
Felicia Scaggs Huang, David I. Bernstein, Karen S. Slobod, Allen Portner, Toru Takimoto, Charles J. Russell, Michael Meagher, Bart G. Jones, Robert E. Sealy, Christopher Coleclough, Kristen Branum, Michelle Dickey, Kristen Buschle, Monica McNeal, Mat Makowski, Aya Nakamura, Julia L. Hurwitz
Summary: The study demonstrated that SeVRSV vaccine was well-tolerated in healthy adults with only mild to moderate reactions and no severe adverse events. Transient vaccine genome detection was observed due to preexisting immunity towards hPIV-1 and RSV in adults. Minimal antibody responses to SeV and negligible responses to RSV F were observed.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Vadim Ivanov, Antonius G. P. Oomens, James F. Papin, Rachel Staats, Darlene N. Reuter, Zhongxin Yu, Pedro A. Piedra, Robert C. Wellliver
Summary: RSV is a major viral respiratory pathogen for infants and children, with no licensed vaccine available. A vaccine has been developed using a human RSV strain with the M protein gene deleted, preventing viral replication. Vaccination led to reduced illness signs and viral replication in infected animals, supporting further development for human use.
Article
Immunology
Ann R. Falsey, Edward E. Walsh, Daniel A. Scott, Alejandra Gurtman, Agnieszka Zareba, Kathrin U. Jansen, William C. Gruber, Philip R. Dormitzer, Kena A. Swanson, Qin Jiang, Emily Gomme, David Cooper, Beate Schmoele-Thoma
Summary: The safety and immunogenicity of an investigational bivalent prefusion F vaccine (RSVpreF) was assessed in healthy adults, with positive results in older adults, supporting its potential to protect against RSV disease.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
James Baber, Mark Arya, Yuben Moodley, Anna Jaques, Qin Jiang, Kena A. Swanson, David Cooper, Mohan S. Maddur, Jakob Loschko, Alejandra Gurtman, Kathrin U. Jansen, William C. Gruber, Philip R. Dormitzer, Beate Schmoele-Thoma
Summary: The stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate was well tolerated and elicited strong and persistent serum neutralizing responses in adults aged 65-85, with or without adjuvant. Adjuvanted formulations did not show additional enhancement of immune responses.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Sitthichai Kanokudom, Suvichada Assawakosri, Nungruthai Suntronwong, Chompoonut Auphimai, Pornjarim Nilyanimit, Preeyaporn Vichaiwattana, Thanunrat Thongmee, Ritthideach Yorsaeng, Donchida Srimuan, Thaksaporn Thatsanatorn, Sirapa Klinfueng, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan
Summary: This study evaluated the booster effect of different vaccine platforms in healthy adults who had received a full dose of inactivated vaccine. The viral vector and mRNA vaccine boosters showed greater immunogenicity compared to the inactivated vaccine. In addition, the vaccinated serum had a high neutralization activity against SARS-CoV-2 wild-type and variants.
Article
Agriculture, Dairy & Animal Science
Sherri A. Powledge, Taylor B. McAtee, Amelia R. Woolums, T. Robin Falkner, John T. Groves, Merilee Thoresen, Robert Valeris-Chacin, John T. Richeson
Summary: Vaccination with modified-live virus (MLV) did not have a clear impact on the health or growth of high-risk calves, but intranasal MLV vaccination was associated with increased carriage of Histophilus somni (Hs) in the naris and reduced culture of Mannheimia haemolytica (Mh) from lung tissue samples. This suggests that intranasal MLV vaccination can alter the microbial community in the respiratory tract of cattle.
JOURNAL OF ANIMAL SCIENCE
(2022)
Article
Multidisciplinary Sciences
Hai Li, Hu Ren, Yan Zhang, Lei Cao, Wenbo Xu
Summary: In this study, intranasal immunization with the recombinant protein CTA1-DD-RBF in mice effectively stimulated specific immune responses and generated protective immunity without inducing lung immunopathology. Compared to other proteins, CTA1-DD-RBF exhibited superior immune protection.
SCIENTIFIC REPORTS
(2021)
Article
Microbiology
Fengjia Chen, Hae-Ran Park, Hyun Jung Ji, Yeongkag Kwon, Min-Kyu Kim, Joon Young Song, Ki Bum Ahn, Ho Seong Seo
Summary: Respiratory syncytial virus (RSV) is a common respiratory pathogen that causes lower respiratory diseases. This study developed an RSV vaccine using gamma irradiation, but found that it induced more adverse effects compared to traditional formalin inactivation, including weight loss, eosinophil infiltration, and mucus secretion. The gamma irradiation also caused significant conformational changes in the vaccine. These findings highlight the importance of considering biochemical actions in the development of RSV vaccines.
MICROBIOLOGY SPECTRUM
(2023)
Article
Virology
Valentina Eberlein, Mareike Ahrends, Lea Bayer, Julia Finkensieper, Joana Kira Besecke, Yaser Mansuroglu, Bastian Standfest, Franziska Lange, Simone Schopf, Martin Thoma, Jennifer Dressman, Christina Hesse, Sebastian Ulbert, Thomas Grunwald
Summary: RSV is a common cause of respiratory tract infections in the elderly and children. A recent study explored the use of a mucosal vaccine using low-energy electron irradiated RSV formulated with phosphatidylcholine-liposomes. The results showed no adverse effects and an efficient induction of antibodies in mice, indicating the potential of this vaccine in protecting against RSV.
Article
Microbiology
Shengwei Jin, Hui An, Tong Zhou, Ting Li, Mengzhen Xie, Saijing Chen, Chengshui Chen, Binyu Ying, Zhangye Xu, Xiaokun Li, Ming Li
Summary: The study revealed diverse clinical and immunological responses to COVID-19 infection based on sex and age categories. Female patients showed milder disease severity, negative associations with inflammatory responses, and liver damage. On the other hand, older patients exhibited compromised immune responses, negative associations with CD8(+) T cell count, but positive associations with inflammatory responses and liver damage.
Article
Immunology
Xin Cheng, Gan Zhao, Aihua Dong, Zhonghuai He, Jiarong Wang, Brian Jiang, Bo Wang, Miaomiao Wang, Xuefen Huai, Shijie Zhang, Shuangshuang Feng, Hong Qin, Bin Wang
Summary: This study conducted a first-in-human trial to evaluate the safety and immunogenicity response of the BARS13 vaccine in healthy adults. The vaccine demonstrated good safety and tolerability, and there were no significant differences in adverse reaction severity or frequency between different dose groups. The immune response in repeat-dose recipients showed potential for further study and guiding the dose selection for future studies.
Article
Multidisciplinary Sciences
Puwich Chaikhumwang, Adthakorn Madapong, Kepalee Saeng-chuto, Dachrit Nilubol, Angkana Tantituvanont
Summary: This study evaluated the immune responses and protective efficacy of intranasal administration of inactivated porcine reproductive and respiratory syndrome virus (PRRSV) loaded in polylactic acid nanoparticles combined with heat-labile enterotoxin subunit B and dimethyldioctadecylammonium bromide. The results showed that this method induced higher levels of interferon-gamma-producing cells and antibodies, and provided better protection against viral infection and lung lesions.
SCIENTIFIC REPORTS
(2022)
Article
Virology
Hortense Petat, Vincent Gajdos, Francois Angoulvant, Pierre-Olivier Vidalain, Sandrine Corbet, Christophe Marguet, Jacques Brouard, Astrid Vabret, Meriadeg Ar Gouilh
Summary: The study found that in infants with acute bronchiolitis, 90% tested positive for respiratory syncytial virus and 34% for human rhinovirus, with a higher risk of HRV infection in the absence of RSV. This suggests the presence of interference or exclusion mechanisms between HRV and RSV.
Article
Biochemistry & Molecular Biology
Cyril Le Nouen, Christine E. Nelson, Xueqiao Liu, Hong-Su Park, Yumiko Matsuoka, Cindy Luongo, Celia Santos, Lijuan Yang, Richard Herbert, Ashley Castens, Ian N. Moore, Temeri Wilder-Kofie, Rashida Moore, April Walker, Peng Zhang, Paolo Lusso, Reed F. Johnson, Nicole L. Garza, Laura E. Via, Shirin Munir, Daniel L. Barber, Ursula J. Buchholz
Summary: This study generated a pediatric SARS-CoV-2 vaccine candidate using a live-attenuated parainfluenza virus vector, and evaluated its immunogenicity and protective efficacy in rhesus macaques. The vaccine induced strong mucosal and systemic immune responses, including neutralizing antibodies and T cell responses. Immunized macaques showed undetectable viral replication after challenge. The vaccine will be clinically evaluated as an intranasal vaccine for pediatric use.